Tandem Diabetes Care (TNDM) Cash from Operations Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 37.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.56% |
| Dec 31, 2025 | 18.92% |
| Sep 30, 2025 | -29.85% |
| Jun 30, 2025 | -50.02% |
| Mar 31, 2025 | -49.25% |
| Dec 31, 2024 | -18.28% |
| Sep 30, 2024 | -7.78% |
| Jun 30, 2024 | -29.71% |
| Mar 31, 2024 | -31.59% |
| Dec 31, 2023 | -35.24% |
| Sep 30, 2023 | -84.43% |
| Jun 30, 2023 | -34.03% |
| Mar 31, 2023 | 3.87% |
| Dec 31, 2022 | -33.11% |
| Sep 30, 2022 | 1.32% |
| Jun 30, 2022 | 24.59% |
| Mar 31, 2022 | 74.86% |
| Dec 31, 2021 | 11.58% |
| Sep 30, 2021 | 128.16% |
| Jun 30, 2021 | 84.67% |
| Mar 31, 2021 | 63.08% |
| Dec 31, 2020 | 49.01% |
| Sep 30, 2020 | 40.37% |
| Jun 30, 2020 | 45.13% |
| Mar 31, 2020 | 0.29% |
| Dec 31, 2019 | 50.83% |
| Sep 30, 2019 | 48.40% |
| Jun 30, 2019 | 31.32% |
| Mar 31, 2019 | 36.29% |
| Dec 31, 2018 | 50.06% |
| Sep 30, 2018 | 37.76% |
| Jun 30, 2018 | 28.97% |
| Mar 31, 2018 | 7.33% |
| Dec 31, 2017 | 4.91% |
| Sep 30, 2017 | -11.88% |
| Jun 30, 2017 | 5.36% |
| Mar 31, 2017 | -7.06% |
| Dec 31, 2016 | -1.93% |
| Sep 30, 2016 | -18.34% |
| Jun 30, 2016 | 3.82% |
| Mar 31, 2016 | -21.86% |